Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: Results of a phase II clinical trial

Retina

Volumn 32, Issue 5, 2012, Pages 996-1006

  Toy, Brian C ^a   Koo, Euna ^a   Cukras, Catherine ^a   Meyerle, Catherine B ^a   Chew, Emily Y ^a   Wong, Wai T ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

anti VEGF; clinical trial; idiopathic macular telangiectasia; IMT2; ranibizumab

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CHEMOSIS; CLINICAL ARTICLE; CONFOCAL LASER SCANNING OPHTHALMOSCOPE; CORNEA INJURY; DISEASE CLASSIFICATION; EYE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC MACULAR TELANGIECTASIA; MACHINE; MALE; NONNEOVASCULAR IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2; OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PHASE 2 CLINICAL TRIAL; RETINA MACULOPATHY; TELANGIECTASIA; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CAPILLARY PERMEABILITY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; RETINAL TELANGIECTASIS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84860837379     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31824690a8     Document Type: Article

References (35)

1. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiec-tasis. Update of classification and follow-up study. Ophthalmology 1993;100:1536-1546. (Pubitemid 23292864)
2. Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic mac-ular telangiectasia. Arch Ophthalmol 2006;124:450-460.
3. Klein R, Blodi BA, Meuer SM, et al. The prevalence of mac-ular telangiectasia type 2 in the Beaver Dam eye study. Am J Ophthalmol 2010;150:55-62.e52.
4. Aung KZ, Wickremasinghe SS, Makeyeva G, et al. The prevalence estimates of macular telangiectasia type 2: the Melbourne Collaborative Cohort Study. Retina 2010;30:473-478.
5. Clemons TE, Gillies MC, Chew EY, et al. Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel project report no. 2. Ophthalmic Epidemiol 2010;17:66-73.
6. Wong WT, Forooghian F, Majumdar Z, et al. Fundus auto-fluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. Am J Ophthalmol 2009;148:573-583.
7. Parmalee NL, Schubert C, Merriam JE, et al. Analysis of candidate genes for macular telangiectasia type 2. Mol Vis 2010; 16:2718-2726.
8. Powner MB, Gillies MC, Tretiach M, et al. Perifoveal Muller cell depletion in a case of macular telangiectasia type 2. Ophthalmology 2010;117:2407-2416.
9. Eliassi-Rad B, Green WR. Histopathologic study of presumed parafoveal telangiectasis. Retina 1999;19:332-335. (Pubitemid 30368120)
10. Green WR, Quigley HA, De la Cruz Z, Cohen B. Parafoveal retinal telangiectasis. Light and electron microscopy studies. Trans Ophthalmol Soc U K 1980;100:162-170. (Pubitemid 11128688)
11. Schlingemann RO, Witmer AN. Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 2009;175:253-267.
12. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 2008;92:941-945. (Pubitemid 351969675)
13. Charbel Issa P, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coherence tomography after intravi-treal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007;114:1736-1742. (Pubitemid 47332685)
14. Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 2008;246:1189-1193.
15. Jorge R, Costa RA, Calucci D, Scott IU. Intravitreal bevacizu-mab (Avastin) associated with the regression of subretinal neo-vascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 2007;245:1045-1048. (Pubitemid 46979541)
16. Ruys J, De Laey JJ, Vanderhaeghen Y, Van Aken EH. Intra-vitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with cho-roidal neovascular membrane. Eye (Lond) 2007;21:1433-1434. (Pubitemid 350066483)
17. Kovach JL, Rosenfeld PJ. Bevacizumab (Avastin) therapy for idiopathic macular telangiectasia type Ii. Retina 2009;29: 27-32.
18. Mandal S, Venkatesh P, Abbas Z, et al. Intravitreal bevacizu-mab (Avastin) for subretinal neovascularization secondary to type 2a idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2007;245:1825-1829. (Pubitemid 350154017)
19. Matsumoto Y, Yuzawa M. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 2010; 54:320-324.
20. Matt G, Sacu S, Ahlers C, et al. Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular tel-angiectasia type 2. Eye (Lond) 2010;24:1535-1541; quiz 1542.
21. Charbel Issa P, Finger RP, Kruse K, et al. Monthly ranibizu-mab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 2011;151: 876-886.e871.
22. Karagiannis D, Georgalas I, Ladas I, et al. A case of sub-retinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis. Clin Interv Aging 2009;4:63-65.
23. Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. Graefes Arch Clin Exp Ophthalmol 2009;247:1567-1569.
24. Lira RP, Silva VB, Cavalcanti TM, et al. Intravitreous ranibi-zumab as treatment for macular telangiectasia type 2. Arch Ophthalmol 2010;128:1075-1078.
25. Mavrakanas N, Mendrinos E, Pournaras CJ, Salzmann J. Intra-vitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangi-ectasia type 2a. Acta Ophthalmol 2009;87:930-932.
26. He YG, Wang H, Zhao B, et al. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2010; 248:1519-1521.
27. Rishi P, Shroff D, Rishi E. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idi-opathic macular telangiectasia. Graefes Arch Clin Exp Oph-thalmol 2008;246:619-621.
28. Vujosevic S, Midena E, Pilotto E, et al. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Invest Ophthalmol Vis Sci 2006;47: 3044-3051. (Pubitemid 351639784)
29. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS One 2008;3. e3554.
30. Charbel Issa P, Helb HM, Holz FG, Scholl HP. Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol 2008; 145:169-175.
31. Charbel Issa P, Holz FG, Scholl HP. Metamorphopsia in patients with macular telangiectasia type 2. Doc Ophthalmol 2009;119: 133-140.
32. Finger RP, Charbel Issa P, Fimmers R, et al. Reading performance is reduced by parafoveal scotomas in patients with mac-ular telangiectasia type 2. Invest Ophthalmol Vis Sci 2009;50: 1366-1370.
33. Watzke RC, Klein ML, Folk JC, et al. Long-term juxtafoveal retinal telangiectasia. Retina 2005;25:727-735. (Pubitemid 41254542)
34. Rapkin JS, Hirsh DK, Curry S. Idiopathic juxtafoveal telangi-ectasia and positional visual disturbance. Retina 1998;18: 183-184. (Pubitemid 28182790)
35. Sindt SJ, Oh K. Idiopathic juxtafoveal retinal telangiectasis: case report and literature review. Optometry 2001;72:228-233. (Pubitemid 33595166)